Therapeutics ID Nelson Answers – Flashcards
Unlock all answers in this set
Unlock answers| Pathogens of Encephalitis |
Viral
Bacterial Neonates: Group B Streptococcus, Listeria monocytogenes, Citrobacter Others: Borrelia burgdorferi, Bartonella henselae, Rickettsia rickettsii, Mycoplasma pneumoniae |
| Clinical Presentation of Encephalitis |
|
| Encephalitis Diagnosis |
|
| Encephalitis CNS Findings |
|
| Encephalitis Treatment |
Support Measures
Empiric Acyclovir
|
| Signs/Symptoms of Bacterial Meningitis |
|
| Physical Exam for Bacterial Meningitis |
Kernig's Sign Brudzinski's Neck Sign
Both will hurt if they have meningitis |
| Most Common Bacterial Pathogens of Meningitis |
|
| Normal CSF Lab Results |
WBCs < 5 (adults) < 20 (newborns)
Diff 70% Lymphocytes 30% Monocytes Protein < 50
Glucose 2/3 serum |
| Bacterial Meningitis Lab Results |
WBCs 400-100,000
Diff 80-90% Neutrophils (PMNs)
Protein Mild to marked elevation (80-500)
Glucose < 1/2 serum |
| Top 3 Infectious Bacteria that cause Meningitis in Neonates |
|
| Characteristics of Pneumococcal Meningitis |
Streptococcus pneumoniae Most Common Meningitis
Known to Affect:
Causes neurologic damage (deafness to severe brain damage)
|
| Characteristics of Meningococcal Meningitis |
|
| Clinical Signs of Meningococcal Meningitis |
|
| Group B Strep Meningitis |
Streptococcus agalactiae
|
| Listeria Meningitis |
|
| Aerobic G- Bacilli that cause Meningitis |
In Neonates
Head trauma or Neurosurgery Patients
|
Empiric Meningitis Therapy: < 1 month Common Bacteria and Treatment |
S. agalactiae E. coli Listeria monocytogenes Klebsiella
Ampicillin + Cefotaxime or Aminoglycoside |
Empiric Meningitis Therapy: 1-23 months Common Bacteria and Treatment |
S. pneumoniae Neisseria meningitidis S. agalactiae H. influenzae type B E. coli
Vancomycin + Ceftriaxone or Cefotaxime |
Empiric Meningitis Therapy: 2-50 yrs Common Bacteria and Treatment |
N. meningitidis S. pneumoniae
Vancomycin + Ceftriaxone or Cefotaxime |
Empiric Meningitis Therapy: > 50 yrs Common Bacteria and Treatment |
S. pnuemoniae N. meningitidis Listeria monocytogenes Aerobic G- bacilli
Vancomycin + Ampicillin + Ceftriaxone or Cefotaxime |
Empiric Meningitis Therapy: Basilar Skull Fracture Common Bacteria and Treatment |
S. pneumoniae H. influenzae Group A Streptococcus pyogenes
Vancomycin + Ceftriaxone or Cefotaxime |
Empiric Meningitis Therapy: Penetrating Head Trauma Common Bacteria and Treatment |
Staph. aureus Coagulase - Staph. Aerobic G - (including P. aeruginosa)
Vancomycin + Cefepime, Ceftazidime, or Meropenem
Important to cover for MRSA and P. aeruginosa
|
Empiric Meningitis Therapy: Post-Neurosurgery Common Bacteria and Treatment |
Aerobic G- bacilli Staph. aureus Coagulase - Staph.
Vancomycin + Ceftazidime, Cefepime, or Meropenem
Important to cover MRSA and P. aeruginosa |
Empiric Meningitis Therapy: CSF Shunt Common Bacteria and Treatment |
Coagulase - Staph. Staph. aureus Aerobic G- bacilli Propionibacterium acnes
Vancomycin + Cefepime, Ceftazidime, or Meropenem
Important to cover MRSA and P. aeruginosa |
Targeted Therapy for Meningitis Streptococcus pneumoniae |
Vancomycin + 3rd Gen Cephalosporin |
Targeted Therapy for Meningitis Neisseria meningitidis |
| 3rd Gen Cephalosporin |
Targeted Therapy for Meningitis Listeria monocytogenes |
Ampicillin OR Penicillin G
Consider adding an aminoglycoside to these |
Targeted Therapy for Meningitis Streptococcus agalactiae |
Ampicillin OR Penicillin G
Consider adding an aminoglycoside to these |
Targeted Therapy for Meningitis Haemophilus influenzae |
| 3rd Gen Cephalosporin |
Targeted Therapy for Meningitis Escherichia coli |
| 3rd Gen Cephalosporin |
| Antibiotic CSF Penetration: Able to achieve Therapeutic Concentrations |
|
| Antibiotic CSF Penetration: Not able to achieve Therapeutic Concentrations |
|
| Antibiotic CSF Penetration: Good if inflammation present |
|
| 3 Baseline Clinical Features Associated with Adverse Outcomes |
|
| Length of Therapy: Neisseria meningitidis |
| 7 days |
| Length of Therapy: Haemophilus influenzae |
| 7 days |
| Length of Therapy: Streptococcus pneumoniae |
| 10-14 days |
Length of Therapy: Streptococcus agalaciae |
| 14-21 days |
| Length of Therapy: Aerobic G- Bacilli |
| 21 days |
| Length of Therapy: Listeria monocytogenes |
| > 21 days |
| In Meningitis, what criteria must be met before the patient can be considered for outpatient therapy? |
|
| Vaccine Prevention: Haemophilus influenzae type B |
| Infants |
| Vaccine Prevention: Streptococcus pneumoniae |
Infants - haven't completed vaccine series Elderly - vaccine may be decreasing in effect |
| Vaccine Prevention: Neisseria meningitidis |
| Teenagers |